Abstract
BACKGROUND:This study assessed the effectiveness of the use of ketorolac
tromethamine to reduce retinopathy of prematurity (ROP) incidence and its
progression to more severe forms. METHODS:Forty-seven preterm newborn infants
with a birth weight (BW) of 1,000 grams or less and/or a gestational age (GA) of
29 weeks or less were enrolled in the study when avascular retina zone I or ROP
any stage were diagnosed at screening. Studied infants were randomized to receive
ketorolac tromethamine ophthalmic solution in one eye and a drop of placebo in
the other eye, until ROP requiring treatment or full retinal vascularization was
diagnosed. RESULTS:Only 2 newborn infants did not develop ROP. Among 45 newborn
infants who developed ROP, 6 showed different ROP staging between the two eyes, 4
of which had a better outcome in the eye receiving ketorolac tromethamine. The
differences between ROP stagings were not significant even when analyzed by GA
and BW subgroups. No significant treatment-related side effects occurred.
CONCLUSION:This report suggests that ketorolac tromethamine ophthalmic solution
cannot reduce the risk of developing severe ROP in preterm infants.
Lingua originale | English |
---|---|
pagine (da-a) | 1-5 |
Numero di pagine | 5 |
Rivista | JOURNAL OF PEDIATRIC OPHTHALMOLOGY & STRABISMUS |
Stato di pubblicazione | Pubblicato - 2010 |
Keywords
- Ketorolac Tromethamine